GenPath logo in conjunction with oncology

OnkoSightTM Exon Coverage

OnkoSightTM panels are targeted assays that are meant to be highly actionable and reduce the number of unclear variant results. To that end, coverage of the genes included on OnkoSightTM panels has been carefully selected based on the actionable mutations recommended in established national guidelines and published literature.

ONKOSIGHT MYELOID DISORDER PANEL

GENE EXON COVERED
ABL1 4, 5, 6
ASXL1 12
BCOR 2-15
BCORL1 1-12
BRAF 15
CALR 9
CBL 8, 9
CDKN2A 1, 2
CSF3R 14-17
DNMT3A 2-23
ETV6 1-8
EZH2 2-20
FBXW7 9-11
FLT3 13-15, 20
GATA2 2-4, 6
HRAS 2, 3
IDH1 4
IDH2 4
JAK2 12, 14
KIT 2, 8-11, 13, 17
KRAS 2, 3
MPL 10
MYD88 3-5
NPM1 11
NRAS 2, 3
PHF6 2-10
PTEN 5, 7
PTPN11 3, 13
RUNX1 2-9
SETBP1 4
SF3B1 13-16
SRSF2 1
TET2 3-11
TP53 2-11
U2AF1 2, 6
WT1 7, 9
ZRSR2 1-11

ONKOSIGHT SOLID TUMOR PANEL

GENE EXON COVERED
AKT1 3
ALK 20, 22-25
BRAF 11 and 15
CTNNB1 3
DDR2 5, 8, 13, 15, 17
EGFR 7, 12, 15, 18-21
EPHA2 5
ERBB2 19-21
ESR1 7, 9, 10
FGFR1 5, 8
FGFR2 7, 9, 12
FGFR3 7, 9, 14, 18
GNA11 5
GNAQ 5
HRAS 2, 3
IDH1 4
IDH2 4
KIT 9, 11, 13, 14, 17, 18
KRAS 2, 3, 4
MAP2K1 2, 3, 6
MET 2, 14, 16, 19
MTOR 44, 53
NOTCH1 26
NRAS 2, 3, 4
PDGFRA 12, 14, 15, 18
PIK3CA 2, 3, 6, 10, 21
PTEN 9-2
RAC1 2
RET 10, 11, 13, 15, 16
ROS1 38
TP53 2, 4-11

Next-generation sequencing provides increased gene coverage compared to other testing methods such as PCR. OnkoSight panels include the latest actionable biomarkers, improving coverage across genes like EGFR, KRAS, and NRAS.

Onkosight Coverage
EGFR: EXON 12 EXON 15 EXON 18 EXON 19 EXON 20 EXON 21
Targeted PCR Coverage
©2019 GenPath, a division of BioReference Laboratories Inc., an OPKO Health Company